Craig Coady knows the exact sound of a life slipping away. It is the silence in a bedroom where a child should be waking up. It is the quiet that followed the death of his 13-year-old son, Rory, who passed away in his sleep from Friedreich’s ataxia last September. Now, Coady is fighting to ensure that silence does not claim his 16-year-old son, Paudie.

Paudie is currently battling the same aggressive, rare genetic disorder. The disease is relentless. It steals mobility, coordination, and eventually, the heart’s ability to function. For the Coady family, time is not a luxury; it is a dwindling resource.

Following a recent meeting with Taoiseach Micheál Martin, Coady is pinning his hopes on the approval of Skyclarys, a drug that has shown the potential to slow the disease’s progression by 50 percent. The stakes are absolute. For Paudie, this medicine is the difference between a future and a fading memory.

The Promise of a Faster Review

Access to new medications in Ireland often moves at a glacial pace. The HSE drugs committee was not scheduled to deliberate on Skyclarys until September. For a family watching a child lose the ability to write and walk within a single year, that wait felt like a death sentence.

Coady’s plea to the Taoiseach appears to have shifted the timeline. According to Coady, the Taoiseach has promised that the committee will now review the drug in July. There is even hope that the meeting could be pulled forward to the end of June.

"The Taoiseach has promised me that it will be on the list in July," Coady said. He described the meeting as deeply emotional. Martin, a father himself, recognized the urgency. Friedreich’s ataxia does not wait for bureaucracy.

A Disease That Doesn’t Wait

Friedreich’s ataxia is a cruel thief. It causes progressive damage to the nervous system. It forces children to trade football pitches for wheelchairs. It turns simple tasks like holding a pen into impossible feats.

Coady first noticed the signs during a friendly football match. Paudie was leaning forward, struggling to find his balance. Two days later, a neurologist at Cork University Hospital was 90 percent certain of the diagnosis. The confirmation arrived five weeks later.

Since then, the deterioration has been rapid. Paudie could write a year ago. Today, he cannot. The disease is moving faster than the system designed to treat it.

The Weight of a Price Tag

Coady’s struggle is compounded by a history of profound loss. His wife, Della, is currently receiving round-the-clock care for Huntington’s disease in Dublin. The family has endured more than most could bear.

"If there’s a price tag on every child in this country, it’s a sorry country," Coady said. He is not asking for charity. He is asking for a chance.

Clinical evidence suggests that Skyclarys can help patients regain lost function. Some who were unable to walk have found their footing again. For Paudie, the drug is not just a treatment. It is a lifeline.

Key Takeaways

  • Urgent Review: The HSE drugs committee is now expected to deliberate on the approval of Skyclarys in July, with potential for an earlier date.
  • Proven Efficacy: The drug is reported to slow the progression of Friedreich’s ataxia by 50 percent and support heart health.
  • Family Crisis: Craig Coady is advocating for his 16-year-old son, Paudie, after already losing his younger son, Rory, to the same genetic condition.

As June draws to a close, the Coady family remains in a state of suspended animation. The promise of a meeting is a start. But for a father who has already buried one son, the only metric that matters is the day the medicine finally arrives.